Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer

BACKGROUND: In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden. METHODS: Patients with previously untreated metastatic PDAC enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Kimberly, Chiarella, Anna M, Cleary, James M, Horick, Nora, Weekes, Colin, Abrams, Thomas, Blaszkowsky, Lawrence, Enzinger, Peter, Giannakis, Marios, Goyal, Lipika, Meyerhardt, Jeffrey A, Rubinson, Douglas, Yurgelun, Matthew B, Goessling, Wolfram, Giantonio, Bruce J, Brais, Lauren, Germon, Victoria, Stonely, Danielle, Raghavan, Srivatsan, Bakir, Basil, Das, Koushik, Pitarresi, Jason R, Aguirre, Andrew J, Needle, Michael, Rustgi, Anil K, Wolpin, Brian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166179/
https://www.ncbi.nlm.nih.gov/pubmed/36807743
http://dx.doi.org/10.1093/oncolo/oyad002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166179/
https://www.ncbi.nlm.nih.gov/pubmed/36807743
http://dx.doi.org/10.1093/oncolo/oyad002

Ejemplares similares